eCite Digital Repository

Non-steroid agents for idiopathic pulmonary fibrosis (Intervention Review)

Citation

Spagnolo, P and Del Giovane, C and Luppi, F and Cerri, S and Balduzzi, S and Walters, EH and D'Amico, R and Richeldi, L, Non-steroid agents for idiopathic pulmonary fibrosis (Intervention Review), Cochrane Database of Systematic Reviews, 2010, (9) EJ ISSN 1469-493X (2010) [Refereed Article]

PDF
Restricted - Request a copy
670Kb
  

Copyright Statement

The definitive published version is available online at: http://onlinelibrary.wiley.com/

Official URL: http://onlinelibrary.wiley.com/o/cochrane/clsysrev...

DOI: doi:10.1002/14651858.CD003134.pub2

Abstract

Background Idiopathic pulmonary fibrosis is a chronic progressive lung disease with poor outcome and no effective treatment to date. This is an update of a Cochrane Review first published in 2003. Objectives To assess the efficacy of non-steroid agents in adults with idiopathic pulmonary fibrosis. Search strategy We searched the Cochrane Airways Group Register (30March 2010), the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library, Issue 1, 2010), Ovid MEDLINE to March week 5, 2010, EMBASE to week 13, 2010 and PubMed to April 2010, with additional handsearching, including abstracts of international conferences. We also contacted pharmaceutical companies and researchers in the field. Selection criteria Randomised studies comparing non-steroid drugs with placebo or steroids in adults with idiopathic pulmonary fibrosis. Data collection and analysis Two authors independently assessed trial quality, extracted data and assessed risk of bias. We contacted pharmaceutical companies to obtain missing information, if any. We combined survival outcomes using Peto odds ratios or hazard ratios (HR). Main results Fifteen trials involving 10 different drugs were included. Two trials enrolling 1156 patients compared interferon gamma-1beta with placebo: interferon gamma-1beta did not significantly improve survival (HR 0.88, 95%CI 0.47 to 1.64; P = 0.68). Four trials involving 1155 patients compared pirfenidone with placebo. Three trials, conducted in 1046 patients, provided data on progression-free survival: pirfenidone significantly reduced the risk of disease progression by 30% (HR 0.70, 95% CI 0.56 to 0.88, P = 0.002). Data on the effect of pirfenidone on pulmonary function could only be assessed for two studies analysing 314 patients. Forced vital capacity or vital capacity was significantly improved by pirfenidone (mean difference 0.08 L, 95% CI 0.03 to 0.13, P = 0.0006).

Item Details

Item Type:Refereed Article
Research Division:Medical and Health Sciences
Research Group:Cardiorespiratory Medicine and Haematology
Research Field:Respiratory Diseases
Objective Division:Health
Objective Group:Clinical Health (Organs, Diseases and Abnormal Conditions)
Objective Field:Respiratory System and Diseases (incl. Asthma)
Author:Walters, EH (Professor Haydn Walters)
ID Code:66761
Year Published:2010
Web of Science® Times Cited:42
Deposited By:Menzies Institute for Medical Research
Deposited On:2011-02-10
Last Modified:2011-05-03
Downloads:0

Repository Staff Only: item control page